前收盘价格 | 3.51 |
收盘价格 | 3.53 |
成交量 | 67,524 |
平均成交量 (3个月) | 81,166 |
市值 | 1,289,038,464 |
预期市盈率 (P/E Forward) | 59.88 |
价格/销量 (P/S) | 1.32 |
股市价格/股市净资产 (P/B) | 1.06 |
52周波幅 | |
利润日期 | 17 Apr 2025 |
营业毛利率 | -22.05% |
营业利益率 (TTM) | -17.68% |
稀释每股收益 (EPS TTM) | -0.550 |
季度收入增长率 (YOY) | -5.80% |
总债务/股东权益 (D/E MRQ) | 48.54% |
流动比率 (MRQ) | 2.09 |
营业现金流 (OCF TTM) | -36.05 M |
杠杆自由现金流 (LFCF TTM) | -188.42 M |
资产报酬率 (ROA TTM) | -1.77% |
股东权益报酬率 (ROE TTM) | -16.25% |
市场趋势
短期 | 中期 | ||
行业 | Drug Manufacturers - Specialty & Generic (US) | 看跌 | 混合的 |
Drug Manufacturers - Specialty & Generic (全球的) | 看跌 | 混合的 | |
股票 | Evotec SE | 混合的 | 看跌 |
AIStockmoo 评分
分析师共识 | -2.0 |
内部交易活动 | NA |
价格波动 | -2.0 |
技术平均移动指标 | 0.0 |
技术振荡指标 | -4.0 |
平均 | -2.00 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States. |
|
部门 | Healthcare |
行业 | Drug Manufacturers - Specialty & Generic |
投资方式 | Small Core |
机构持股比例 | 2.52% |
所有权
姓名 | 日期 | 持有股份 |
---|---|---|
Lighthouse Investment Partners, Llc | 31 Dec 2024 | 39,803 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合